These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

351 related items for PubMed ID: 12114362

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Higher tobramycin concentration and vibrating mesh technology can shorten antibiotic treatment time in cystic fibrosis.
    Coates AL, Denk O, Leung K, Ribeiro N, Chan J, Green M, Martin S, Charron M, Edwardes M, Keller M.
    Pediatr Pulmonol; 2011 Apr; 46(4):401-8. PubMed ID: 21438171
    [Abstract] [Full Text] [Related]

  • 24. Pharmacokinetics and safety of tobramycin nebulization with the I-neb and PARI-LC Plus in children with cystic fibrosis: A randomized, crossover study.
    van Velzen AJ, Uges JWF, Heijerman HGM, Arets BGM, Nuijsink M, van der Wiel-Kooij EC, van Maarseveen EM, van Zanten GA, Pullens B, Touw DJ, Janssens HM.
    Br J Clin Pharmacol; 2019 Sep; 85(9):1984-1993. PubMed ID: 31112621
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis.
    Hubert D, Leroy S, Nove-Josserand R, Murris-Espin M, Mely L, Dominique S, Delaisi B, Kho P, Kovarik JM.
    J Cyst Fibros; 2009 Sep; 8(5):332-7. PubMed ID: 19651542
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Population pharmacokinetics of tobramycin in patients with and without cystic fibrosis.
    Hennig S, Standing JF, Staatz CE, Thomson AH.
    Clin Pharmacokinet; 2013 Apr; 52(4):289-301. PubMed ID: 23420517
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Administration of aerosolized antibiotics in cystic fibrosis patients.
    Moss RB.
    Chest; 2001 Sep; 120(3 Suppl):107S-113S. PubMed ID: 11555564
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. The influence of breathing mode on tobramycin serum levels using the I-neb AAD system in adults with cystic fibrosis.
    van Velzen AJ, Uges JW, Le Brun PP, Shahbabai P, Touw DJ, Heijerman HG.
    J Cyst Fibros; 2015 Nov; 14(6):748-54. PubMed ID: 25636858
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis.
    Blumer JL, Saiman L, Konstan MW, Melnick D.
    Chest; 2005 Oct; 128(4):2336-46. PubMed ID: 16236892
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.